JPRN-jRCT2080220529
Unknown
Phase 2
Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis - A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Subjects endoscopically diagnosed erosive esophagitis
- Sponsor
- Takeda Pharmaceutical Company Limited
- Enrollment
- 850
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects endoscopically diagnosed with Los Angeles grade A\-D erosive esophagitis
- •2\. Male or female subject at least 20 years of age at time of obtaining consent
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)on resectable Hepatocellular carcinoma (HCC)MedDRA version: 21.0Level: LLTClassification code: 10019828Term: Hepatocellular carcinoma non-resectable Class: 10029104Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-511538-11-00Institut Gustave Roussy40
Completed
Phase 4
Effect of Haridradi tail in Acne and PigmentatioCTRI/2022/01/039493Ms Ozone Pharmaceuticals Ltd50
Active, not recruiting
Phase 1
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1 Level: LLT Classification code 10064859 Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-GBOctapharma AG5
Active, not recruiting
Phase 1
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immunodeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-FROctapharma AG5
Active, not recruiting
Not Applicable
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-DEOctapharma AG45